Xencor (XNCR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xencor (XNCR)

XNCR 13.69

-1.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: fitzdad55 who wrote (72)	6/28/2016 5:39:04 PM
From: scaram(o)uche	Read Replies (1) of 136

Both of today's PRs emphasized their perceived advantages, using full length antibody constructs. They point to some perceived deficiencies in competitive projects... half life, stability. Then they point to the advantages of having an Fc. Etc. Good deal with Novartis. This is a very nice wrinkle..... "mid single-digit tiered royalties for worldwide sales of the four proprietary Novartis bi-specific molecules, unless Xencor exercises its right to co-detail one of these molecules and share in the costs and U.S. profit." Seems sort of late in the game to be licensing bispecific capacity? This release describes two deals under an umbrella payment, and it's all good for xncr. Feel free to post afmd-related stuff to this thread. We'd all like to see it. Best! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next